Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anti-angiogenic targeted drugs plus PD-1 inhibitors with radiotherapy as neoadjuvant therapy for hepatocellular carcinoma with portal vein thrombosis
ChiCTR2500107260Phase 2Not yet recruiting
- Sponsor
- Beijing Tsinghua Changgung Hospital
- Start
- Aug 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of lenvatinib in hepatocellular carcinoma (HCC) and portal vein tumor thrombosis (PVTT) (2 arms), sponsored by Beijing Tsinghua Changgung Hospital. Primary endpoints: Safety and feasibility and 1-year disease-free survival rate (DFS rate). Planned start Aug 2025; status: not yet recruiting.
02
Drugs
lenvatinib
03
Conditions
hepatocellular carcinoma (HCC)portal vein tumor thrombosis (PVTT)
Beyond the preview
Go deeper on ChiCTR2500107260.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500107260.